Treatment in First Line of Mantle Cell Lymphoma for Patients Under 66 Years by the VAD-CHLORAMBUCIL -Rituximab Regimen Followed by Intensification and Autologous PBSC Transplantation After Marrow Purging With Rituximab
All patients at diagnosis with a stage II, III or IV an arbor disease are treated with 4
cycles of (R VAD +C) .
The responders more than RP > 50% received 2 other cycles before to be intensified with
alkeran 140 mg/ m2 and a 8 grays TBI over 4 days before an autologous PBSCT.The stem cell
collection is realised after a mobilisation with HD Cyclophosphamide (4 mg/m2) after the
four R-(VAD + C) cycles and purged by a rituximab injection 10 days before the collection.
There is an clinical and molecular evaluation of the strategy
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
failure event free survival at 3 years
Remy GRESSIN, MD
Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang GOELAMS
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)